References
- S.A. Ganai, E. Abdullah, R. Rashid, and M. Altaf, Combinatorial in silico strategy towards identifying potential hotspots during inhibition of structurally identical HDAC1 and HDAC2 enzymes for effective chemotherapy against neurological disorders, Front. Mol. Neurosci. 10 (2017), pp. 357. doi:https://doi.org/10.3389/fnmol.2017.00357.
- S. Banerjee, N. Adhikari, S.A. Amin, and T. Jha, Histone deacetylase 8 (HDAC8) and its inhibitors with selectivity to other isoforms: An overview, Eur. J. Med. Chem. 164 (2019), pp. 214–240. doi:https://doi.org/10.1016/j.ejmech.2018.12.039.
- D.H. Kim, M.J. Kim, and H.J. Kwon, Histone deacetylase in carcinogenesis and its inhibitors as anti-cancer agents, J. Biochem. Mol. Biol. 36 (2003), pp. 110–119. doi:https://doi.org/10.5483/bmbrep.2003.36.1.110.
- F. Cao, M.R. Zwinderman, R.V. Merkerk, P.E. Ettema, W.J. Quax, and F.J. Dekker, Inhibitory selectivity among class I HDACs has a major impact on inflammatory gene expression in macrophages, Eur. J. Med. Chem. 177 (2019), pp. 457–466. doi:https://doi.org/10.1016/j.ejmech.2019.05.038.
- S. Yoon and G.H. Eom, HDAC and HDAC inhibitor: From cancer to cardiovascular diseases, Chonnam. Med. J. 52 (2016), pp. 1–11. doi:https://doi.org/10.4068/cmj.2016.52.1.1.
- N. Reichert, M.A. Choukrallah, and P. Matthias, Multiple roles of class I HDACs in proliferation, differentiation, and development, Cell. Mol. Life Sci. 69 (2012), pp. 2173–2187. doi:https://doi.org/10.1007/s00018-012-0921-9.
- T. Wagner, P. Brand, T. Heinzel, and O.H. Krämer, Histone deacetylase 2 controls p53 and is a critical factor in tumorigenesis, Biochim. Biophys. Acta Rev. Cancer Cancer 1846 (2014), pp. 524–538. doi:https://doi.org/10.1016/j.bbcan.2014.07.010.
- D. Liu, H. Tang, X.Y. Li, M.F. Deng, N. Wei, X. Wang, Y.F. Zhou, D.Q. Wang, P. Fu, J.Z. Wang, and S.S. Hébert, Targeting the HDAC2/HNF-4A/miR-101b/AMPK pathway rescues tauopathy and dendritic abnormalities in Alzheimer’s disease, Mol. Ther. 25 (2017), pp. 752–764. doi:https://doi.org/10.1016/j.ymthe.2017.01.018.
- C.M. Trivedi, Y. Luo, Z. Yin, M. Zhang, W. Zhu, T. Wang, T. Floss, M. Goettlicher, P.R. Noppinger, W. Wurst, and V.A. Ferrari, Hdac2 regulates the cardiac hypertrophic response by modulating Gsk3β activity, Nat. Med. 13 (2007), pp. 324–331. doi:https://doi.org/10.1038/nm1552.
- A. Abend and I. Kehat, Histone deacetylases as therapeutic targets — From cancer to cardiac disease, Pharmacol. Ther. 147 (2015), pp. 55–62. doi:https://doi.org/10.1016/j.pharmthera.2014.11.003.
- S.V. Stoddard, X.A. May, F. Rivas, K. Dodson, S. Vijayan, S. Adhika, K. Parker, and D.L. Watkins, Design of potent panobinostat histone deacetylase inhibitor derivatives: Molecular considerations for enhanced isozyme selectivity between HDAC2 and HDAC8, Mol. Inform. 38 (2019), pp. 1800080. doi:https://doi.org/10.1002/minf.201800080.
- V. Krieger, A. Hamacher, F. Cao, K. Stenzel, C.G. Gertzen, L.S. Hübner, T. Kurz, H. Gohlke, F.J. Dekker, M.U. Kassack, and F.K. Hansen, Synthesis of peptoid-based class i-selective histone deacetylase inhibitors with chemosensitizing properties, J. Med. Chem. 62 (2019), pp. 11260–11279. doi:https://doi.org/10.1021/acs.jmedchem.9b01489.
- L. Zhou, X. Xu, H. Liu, X. Hu, W. Zhang, M. Ye, and X. Zhu, Prognosis analysis of histone deacetylases mRNA expression in ovarian cancer patients, J. Cancer 9 (2018), pp. 4547. doi:https://doi.org/10.3389/fnmol.2017.00357.
- J. Verma, V.M. Khedkar, and E.C. Coutinho, 3D-QSAR in drug design - A review, Curr. Top. Med. Chem. 10 (2010), pp. 95–115. doi:https://doi.org/10.2174/156802610790232260.
- P.P. Roy, S. Paul, I. Mitra, and K. Roy, On two novel parameters for validation of predictive QSAR models, Molecules 14 (2009), pp. 1660–1701. doi:https://doi.org/10.3390/molecules14051660.
- S.A. Amin, S. Banerjee, N. Adhikari, and T. Jha, Discriminations of active from inactive HDAC8 inhibitors Part II: Bayesian classification study to find molecular fingerprints, SAR QSAR Env. Res. 31 (2020), pp. 245–260. doi:https://doi.org/10.1080/1062936X.2020.1723136.
- H. Pham-The, G. Casañola-Martin, K. Diéguez-Santana, N. Nguyen-Hai, N.T. Ngoc, L. Vu-Duc, and H. Le-Thi-Thu, Quantitative structure–activity relationship analysis and virtual screening studies for identifying HDAC2 inhibitors from known HDAC bioactive chemical libraries, SAR QSAR Env. Res. 28 (2017), pp. 199–220. doi:https://doi.org/10.1080/1062936X.2017.1294198.
- H. Pham-The and H.U. Le-Thi-Thu, Integrating structure and ligand-based approaches for modelling the histone deacetylase inhibition activity of hydroxamic acid derivatives, J. Pharm. Clin. Res. 11 (2018), pp. 198–206. doi:https://doi.org/10.3390/molecules14051660.
- U. Norinder, J.J. Naveja, E. Lopez-Lopez, D. Mucs, and J.L. Medina-Franco, Conformal prediction of HDAC inhibitors, SAR QSAR Env. Res. 30 (2019), pp. 265–277. doi:https://doi.org/10.1080/1062936X.2019.1591503.
- D.T. Anh, P.-T. Hai, D.T.M. Dung, P.T.P. Dung, L.-T.-T. Huong, E.J. Park, H.W. Jun, J.S. Kang, J.-H. Kwon, and T.T. Tung, Design, synthesis and evaluation of novel indirubin-based N-hydroxybenzamides, N-hydroxypropenamides and N-hydroxyheptanamides as histone deacetylase inhibitors and antitumor agents, Bioorg. Med. Chem. Lett. 30 (2020), pp. 127537. doi:https://doi.org/10.1016/j.bmcl.2020.127537.
- T.M.D. Dung, P.T.P. Dung, D.T.K. Oanh, P.T. Hai, T.T.L. Huong, V.D. Loi, H. Hahn, B.W. Han, J. Kim, S.B. Han, and N.H. Nam, Novel 3-substituted-2-oxoindoline-basedN-hydroxypropenamides as histone deacetylase inhibitors and antitumor agents, Med. Chem. 11 (2015), pp. 725–735. doi:https://doi.org/10.2174/1573406411666150702130633.
- D.T.M. Dung, N.V. Huan, D.M. Cam, D.C. Hieu, L.T. Huong, J. Kim, J.E. Choi, J.S. Kang, S.B. Han, and N.H. Nam, Novel hydroxamic acids incorporating 1-((1H-1,2,3-Triazol-4-yl)methyl)- 3-substituted-2-oxoindolines: Synthesis, Biological Evaluation and SAR Analysis, Med. Chem. 14 (2018), pp. 831–850. doi:https://doi.org/10.2174/1573406414666180528111749.
- D.T.M. Dung, P.-T. Hai, D.T. Anh, L.-T.-T. Huong, N.T.K. Yen, B.W. Han, E.J. Park, Y.J. Choi, J.S. Kang, V.-T.-M. Hue, and S.-B. Han, Novel hydroxamic acids incorporating 1-((1H-1,2,3-triazol-4-yl)methyl)-3-hydroxyimino-indolin-2-ones: Synthesis, biological evaluation, and SAR analysis, J. Chem. Sci. 130 (2018), pp. 1–13. doi:https://doi.org/10.1007/s12039-018-1472-x.
- T.T. Huong, D.T. Dung, N.V. Huan, L.V. Cuong, P.T. Hai, L.T. Huong, J. Kim, Y.G. Kim, S.B. Han, and N.H. Nam, Novel N-hydroxybenzamides incorporating 2-oxoindoline with unexpected potent histone deacetylase inhibitory effects and antitumor cytotoxicity, Bioorg. Chem. 71 (2017), pp. 160–169. doi:https://doi.org/10.1016/j.bioorg.2017.02.002.
- T.T. Huong, P.T. Huong, T.P. Thao, P.T. Dung, D.T. Oanh, N.T. Huong, H.V. Quan, T.K. Vu, S.B. Han, J.H. Lee, and S.B. Han, Exploration of some indole-based hydroxamic acids as histone deacetylase inhibitors and antitumor agents, Chem. Pap. 71 (2017), pp. 1759–1769. doi:https://doi.org/10.1007/s11696-017-0172-1.
- ChemDraw Ultra 5.0, Cambridge Soft Corporation, USA, (2010); software available at http://www.cambridgesoft.com (Accessed 20th February 2021).
- Discovery Studio 3.0 (DS 3.0). Accelrys Inc., CA, USA, 2015; software available at http://www.accelrys.com (Accessed 23rd March 2021).
- S. Mondal, S. Banerjee, S.A. Amin, and T. Jha, Structural analysis of arylsulfonamide-based carboxylic acid derivatives: A QSAR study to identify the structural contributors toward their MMP-9 inhibition, Struct. Chem. 32 (2021), pp. 417–430. doi:https://doi.org/10.1007/s11224-020-01635-4.
- S.A. Amin, N. Adhikari, S. Gayen, and T. Jha, First report on the structural exploration and prediction of new BPTES analogs as glutaminase inhibitors, J. Mol. Struct. 1143 (2017), pp. 49–64. doi:https://doi.org/10.1016/j.molstruc.2017.04.020.
- TALETE srl. DRAGON, Milano, Italy, 2007; software available at http://www.talete.mi.it/ (Accessed 8th March 2021)
- STATISTICA Version 7.1, StatSoft, Inc, Tulsa, USA, 2005.
- N. Adhikari, A.K. Halder, C. Mondal, and T. Jha, Structural findings of quinolone carboxylic acids in cytotoxic, antiviral, and anti-HIV-1 integrase activity through validated comparative molecular modeling studies, Med. Chem. Res. 23 (2014), pp. 3096–3127. doi:https://doi.org/10.1007/s00044-013-0897-5
- The simple, user-friendly and reliable online standalone tools freely available at http://dtclab.webs.com/software-tools. (Accessed 2nd August 2021).
- N. Adhikari, A.K. Halder, A. Saha, K.D. Saha, and T. Jha, Structural findings of phenylindoles as cytotoxic antimitotic agents in human breast cancer cell lines through multiple validated QSAR studies, Toxicol. In Vitro 29 (2015), pp. 1392–1404. doi:https://doi.org/10.1016/j.tiv.2015.05.017.
- A. Golbraikh and A. Tropsha, Predictive QSAR modeling based on diversity sampling of experimental datasets for the training and test set selection, Molec. Div. 5 (2000), pp. 231–243. doi:https://doi.org/10.1023/A:1021372108686.
- A. Amin, N. Adhikari, S. Bhargava, T. Jha, and S. Gayen, Designing potential antitrypanosomal thiazol-2-ethylamines through predictive regression based and classification based QSAR analyses, Curr. Drug Discov. Technol. 14 (2017), pp. 39–52. doi:https://doi.org/10.2174/1570163813666161117144137.
- A. Pérez-Garrido, A.M. Helguera, F. Borges, M.N. Cordeiro, V. Rivero, and A.G. Escudero, Two new parameters based on distances in a receiver operating characteristic chart for the selection of classification models, J. Chem. Inf. Model. 51 (2011), pp. 2746–2759. doi:https://doi.org/10.1021/ci2003076.
- T. Fawcett, An introduction to ROC analysis, Patt. Recogn. Lett. 27 (2006), pp. 861–874. doi:https://doi.org/10.1016/j.patrec.2005.10.010.
- S.A. Amin, S. Bhargava, N. Adhikari, S. Gayen, and T. Jha, Exploring pyrazolo[3,4-d]pyrimidine phosphodiesterase 1 (PDE1) inhibitors: A predictive approach combining comparative validated multiple molecular modelling techniques, J. Biomol. Struct. Dyn. 36 (2018), pp. 590–608. doi:https://doi.org/10.1080/07391102.2017.1288659.
- S. Banerjee, S.A. Amin, N. Adhikari, and T. Jha, Essential elements regulating HDAC8 inhibition: A classification based structural analysis and enzyme-inhibitor interaction study of hydroxamate based HDAC8 inhibitors, J. Biomol. Struct. Dyn. 38 (2020), pp. 5513–5525. doi:https://doi.org/10.1080/07391102.2019.1704881.
- R. David and H. Mathew, Extended-connectivityfingerprints, J. Chem. Inf. Model 50 (2010), pp. 742–754. doi:https://doi.org/10.1021/ci100050t.
- S.A. Amin, N. Adhikari, and T. Jha, Exploration of histone deacetylase 8 inhibitors through classification QSAR study: Part II, J. Mol. Struct. 1204 (2020), pp. 127529. doi:https://doi.org/10.1016/j.molstruc.2019.127529.
- SYBYL-X 2.0 Software (2012) Tripos Inc., St. Louis. MO, USA http://www.certara.com (Accessed 16th March 2021).
- N. Adhikari, A.K. Halder, S. Mallick, A. Saha, K.D. Saha, and T. Jha, Robust design of some selective matrix metalloproteinase-2 inhibitors over matrix metalloproteinase-9 through in silico/fragment-based lead identification and de novo lead modification: Syntheses and biological assays, Bioorg. Med. Chem 24 (2016), pp. 4291–4309. doi:https://doi.org/10.1016/j.bmc.2016.07.023
- M.C. Hemmer, V. Steinhauer, and J. Gasteiger, Deriving the 3D structure of organic molecules from their infrared spectra, Vib. Spectrosc. 19 (1999), pp. 151–164. doi:https://doi.org/10.1016/S0924-2031(99)00014-4.
- Z. Hou, Y. Xiang, Y. Wei, C. Zhao, and Z. Zhang, 3D-QSAR and 3D-QSSR studies on a series of HDAC2 inhibitors using Topomer CoMFA. 4th International Conference on Biomedical Engineering and Informatics (BMEI), IEEE 4 (2011), pp. 1811–1814.
- Y. Xiang, Z. Hou, and Z. Zhang, Pharmacophore and QSAR studies to design novel histone deacetylase 2 inhibitors, Chem. Biol. Drug Des. 79 (2012), pp. 760–770. doi:https://doi.org/10.1111/j.1747-0285.2012.01341.x.
- S.B. Nair, M.K. Teli, H. Pradeep, and G.K. Rajanikant, Computational identification of novel histone deacetylase inhibitors by docking based QSAR, Comput. Biol. Med. 42 (2012), pp. 697–705. doi:https://doi.org/10.1016/j.compbiomed.2012.04.001.
- N. Kandakatla and G. Ramakrishnan, Ligand based pharmacophore modelling and virtual screening studies to design novel HDAC2 inhibitors, Adv. Bioinf. 2014 (2014), pp. 1–11. doi:https://doi.org/10.1155/2014/812148.